Disability weights for castration-resistant prostate cancer: an empirical investigation

Authors

  • Ludovica Borsoi Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Milan - Italy https://orcid.org/0000-0001-9478-6451
  • Oriana Ciani Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Milan - Italy https://orcid.org/0000-0002-3607-0508
  • Rocco De Vivo Medical Oncology Unit, AULSS 8 Berica - East District, Vicenza - Italy
  • Giorgio Ivan Russo Urology Section, Department of Surgery, University of Catania, Catania - Italy https://orcid.org/0000-0003-4687-7353
  • Marcello Scarcia Department of Urology, General Regional Hospital “F. Miulli”, Acquaviva delle Fonti, Bari - Italy https://orcid.org/0000-0002-7284-6174
  • Chiara De Fino Janssen-Cilag SpA, Cologno Monzese, Milan - Italy https://orcid.org/0000-0001-5393-8746
  • Patrizia Beccaglia Janssen-Cilag SpA, Cologno Monzese, Milan - Italy
  • Irene Luccarini Janssen-Cilag SpA, Cologno Monzese, Milan - Italy https://orcid.org/0000-0003-4255-459X

DOI:

https://doi.org/10.33393/grhta.2022.2431

Keywords:

Castration-resistant prostate cancer, Disability weights, Disease burden, Person-trade-off, Visual analogue scale

Abstract

Introduction: Health state valuation and diagnostic-therapeutic pathways at the junction between non-metastatic and metastatic castration-resistant prostate cancer (CRPC) are not well documented. We aimed at: (i) estimating the disability weights (DWs) for health states across a continuum of disease from asymptomatic non-metastatic (nmCRPC) to symptomatic metastatic state (mCRPC); (ii) mapping the diagnostic-therapeutic pathway of nmCRPC in Italy.

Methods: Structured qualitative interviews were performed with clinical experts to gather information on nmCRPC clinical pathway. An online survey was administered to clinical experts to estimate DWs for four CRPC health states defined from interviews and literature review (i.e., nmCRPC, asymptomatic mCRPC, symptomatic mCRPC, mCRPC in progression during or after chemotherapy). Clinicians’ preferences for health states were elicited using the Person-Trade-Off (PTO) and Visual Analogue Scale (VAS) methods. DWs associated with each health state, from 0 (best imaginable health state) and 1 (worst imaginable health state), were estimated.

Results: We found that the management of nmCRPC is heterogeneous across Italian regions and hospitals, especially with respect to diagnostic imaging techniques. DWs for PTO ranged from 0.415 (95% confidence interval [CI] 0.208-0.623) in nmCRPC to 0.740 (95% CI 0.560-0.920) in mCRPC, in progression during or after chemotherapy. DWs for VAS ranged between 0.246 (95% CI 0.131-0.361) in nmCRPC to 0.689 (95% CI 0.583-0.795) in mCRPC, in progression during or after chemotherapy.

Conclusions: Estimated DWs suggest that delaying transition to a metastatic state might ease the disease burden at both patient and societal levels.

References

World Bank. World Development Report 1993: Investing in Health. Online https://openknowledge.worldbank.org/handle/10986/5976 (Accessed May 2022)

Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429-445. PMID:8062401

Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, et al. Calculating disability-adjusted life years to quantify burden of disease. Int J Public Health. 2014;59(3):565-569. https://doi.org/10.1007/s00038-014-0552-z PMID:24752429

Essink-Bot ML, Bonsel G. How to derive disability weights (Chapter 9.1). J Immunol. 2002;01(01):449-465.

Murray CJL, Lopez AD; World Health Organization, World Bank & Harvard School of Public Health. (‎1996)‎. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020: summary/edited by Christopher J. L. Murray, Alan D. Lopez. World Health Organization. Online https://apps.who.int/iris/handle/10665/41864 (Accessed May 2022).

Haagsma JA, Polinder S, Cassini A, Colzani E, Havelaar AH. Review of disability weight studies: comparison of methodological choices and values. Popul Health Metr. 2014;12(1):20. https://doi.org/10.1186/s12963-014-0020-2 PMID:26019690

Ock M, Park B, Park H, et al. Disability weights measurement for 289 causes of disease considering disease severity in Korea. J Korean Med Sci. 2019;34(suppl 1):e60. https://doi.org/10.3346/jkms.2019.34.e60 PMID:30923484

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMID:30207593

AIOM-AIRTUM. The numbers of cancer in Italy. 2019 [in Italian]. Online https://www.aiom.it/i-numeri-del-cancro-in-italia/ (Accessed May 2022).

Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4(6):380-384. https://doi.org/10.5489/cuaj.10167 PMID:21191494

Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(12)(suppl 2):S72-S79. https://doi.org/10.3747/co.v17i0.718 PMID:20882137

Xie W, Regan MM, Buyse M, et al; ICECaP Working Group. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35(27):3097-3104. https://doi.org/10.1200/JCO.2017.73.9987 PMID:28796587

Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34(14):1652-1659. https://doi.org/10.1200/JCO.2015.65.7270 PMID:26951312

López-Campos F, Conde-Moreno A, Barrado Los Arcos M, Gómez-Caamaño A, García-Gómez R, Hervás Morón A. treatment landscape of nonmetastatic castration-resistant prostate cancer: a window of opportunity. J Pers Med. 2021;11(11):1190. https://doi.org/10.3390/jpm11111190 PMID:34834544

Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019 Feb;75(2):285-293. https://doi.org/10.1016/j.eururo.2018.07.035 PMID:30119986

Fitzmaurice C, Abate D, Abbasi N, et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749-1768. https://doi.org/10.1001/jamaoncol.2019.2996 PMID:31560378

Haagsma JA, Maertens de Noordhout C, Polinder S, et al. Assessing disability weights based on the responses of 30,660 people from four European countries. Popul Health Metr. 2015;13(1):10. https://doi.org/10.1186/s12963-015-0042-4 PMID:26778920

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. https://doi.org/10.1001/jama.2013.281053 PMID:24141714

Lohr SL. Sampling. Design and analysis. 3rd ed. CRC Press/Chapman & Hall; 2022.

Creswell JW, Poth CN. Qualitative inquiry and research design: choosing among five approaches. SAGE Publications; 2016.

Castleberry A, Nolen A. Thematic analysis of qualitative research data: is it as easy as it sounds? Curr Pharm Teach Learn. 2018;10(6):807-815. https://doi.org/10.1016/j.cptl.2018.03.019PMID:30025784

Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10(10):e0139440. https://doi.org/10.1371/journal.pone.0139440 PMID:26460686

Stouthard M, Essink-Bot M-L, Bonsel G, et al. Disability weights for diseases in The Netherlands. Tijdschr Gerontol Geriatr. 1997;01(01).

Schwarzinger M, Stouthard ME, Burström K, Nord E. Cross-national agreement on disability weights: the European Disability Weights Project. Popul Health Metr. 2003;1(1):9. https://doi.org/10.1186/1478-7954-1-9 PMID:14633276

Haagsma JA, Havelaar AH, Janssen BM, Bonsel GJ. Disability adjusted life years and minimal disease: application of a preference-based relevance criterion to rank enteric pathogens. Popul Health Metr. 2008;6(1):7. https://doi.org/10.1186/1478-7954-6-7 PMID:19114007

EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208. https://doi.org/10.1016/0168-8510(90)90421-9PMID:10109801

Lloyd AJ, Kerr C, Penton J, Knerer G. Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: a survey capturing experiences from a diverse sample of UK patients. Value Health. 2015;18(8):1152-1157. https://doi.org/10.1016/j.jval.2015.08.012 PMID:26686802

Nord E. The person-trade-off approach to valuing health care programs. Med Decis Making. 1995;15(3):201-208. https://doi.org/10.1177/0272989X9501500302 PMID:7564933

van Spijker BA, van Straten A, Kerkhof AJ, Hoeymans N, Smit F. Disability weights for suicidal thoughts and non-fatal suicide attempts. J Affect Disord. 2011 Nov;134(1-3):341-347. https://doi.org/10.1016/j.jad.2011.05.020 PMID.21652085

Froberg DG, Kane RL. Methodology for measuring health-state preferences—I: measurement strategies. J Clin Epidemiol. 1989;42(4):345-354. https://doi.org/10.1016/0895-4356(89)90039-5PMID:2723695

Little RJ, Carpenter JR, Lee KJ. A comparison of three popular methods for handling missing data: complete-case analysis, inverse probability weighting, and multiple imputation. Sociol Methods Res. 2022. https://doi.org/10.1177/00491241221113873

Kendall MG. A new measure of rank correlation. Biometrika. 1938;30(1/2):81-93. https://doi.org/10.2307/2332226

Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3(11):e712-e723. https://doi.org/10.1016/S2214-109X(15)00069-8 PMID:26475018

Associazione Italiana di Oncologia Medica (AIOM). Guidelines – Prostate cancer. 2019 [in Italian]. Online https://www.aiom.it/linee-guida-aiom-carcinoma-della-prostata-2019/ (Accessed May 2022).

Tartarone A, Lerose R, Tartarone M. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management. Med Oncol. 2022;39(7):107. https://doi.org/10.1007/s12032-022-01743-7 PMID:35553247

Cattrini C, Caffo O, De Giorgi U, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers (Basel). 2022;14(7):1792. https://doi.org/10.3390/cancers14071792 PMID:35406564

Brazier J, Deverill M, Green C. A review of the use of health status measures in economic evaluation. J Health Serv Res Policy. 1999;4(3):174-184. https://doi.org/10.1177/135581969900400310 PMID:10538884

Allison PD. Missing data. Sage Publications; 2002. https://doi.org/10.4135/9781412985079

Little RJ, Rubin DB. Statistical analysis with missing data. John Wiley & Sons; 2020.

Additional Files

Published

2022-11-14

How to Cite

1.
Borsoi L, Ciani O, De Vivo R, Russo GI, Scarcia M, De Fino C, Beccaglia P, Luccarini I. Disability weights for castration-resistant prostate cancer: an empirical investigation. Grhta [Internet]. 2022 Nov. 14 [cited 2022 Dec. 6];9(1):146-54. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2431

Issue

Section

Original Research Articles